Latest news with #T1D
Medscape
a day ago
- Health
- Medscape
Novel Survey Effectively Screens Binge Eating in Diabetes
A new diabetes-specific 10-item screening tool demonstrated excellent performance in detecting binge eating disorder in both patients with type 1 diabetes (T1D) and those with type 2 diabetes (T2D), showing strong associations with glycaemic control and mental health outcomes. METHODOLOGY: Although diabetes-specific screening for disordered eating behaviours is advised, the only available tool — the Diabetes Eating Problem Survey–Revised (DEPS-R) — is tailored for patients with T1D on rapid-acting insulin therapy, limiting its applicability across other diabetes types and treatment regimens. Researchers developed a 10-item non–insulin-specific version of the DEPS-R (DEPS-10) and evaluated its screening performance for binge eating disorder in 679 patients with T1D or T2D (mean age, 53.8 years) who had the disease for at least 1 year. The new survey assessed loss of control over eating, dietary and purging behaviours, and challenges in diabetes management. Researchers conducted a receiver operating characteristic curve analysis to test the screening performance of the DEPS-10 and compared it with those of the original DEPS-R and the Problem Areas In Diabetes (PAID) scale. TAKEAWAY: The point prevalence of binge eating disorder was 3.5% in the whole cohort, 2.9% in patients with T1D, and 4.3% in those with T2D. The DEPS-10 showed excellent screening performance for binge eating disorder (area under the curve [AUC], 0.92; P < .001), matching that of the DEPS-R (AUC, 0.92; P < .001) and surpassing that of the PAID scale (AUC, 0.82; P < .001). < .001), matching that of the DEPS-R (AUC, 0.92; < .001) and surpassing that of the PAID scale (AUC, 0.82; < .001). The DEPS-10 showed optimal sensitivity (87.5%) and specificity (86.9%) for detecting binge eating disorder at a cutoff score of greater than or equal to 15; participants with this cutoff score had higher body mass index and A1c level along with a greater psychological burden than those with scores below it. The stepwise approach of first screening with the PAID scale and then applying the DEPS-10 boosted specificity to 94%, compared with 87% when using the DEPS-10 alone and 67% when using the PAID scale alone. IN PRACTICE: "A two-step approach using the PAID followed by the DEPS-10 can be a feasible and time-efficient procedure in routine care," the authors wrote. SOURCE: This study was led by Laura Yvonne Klinker, Diabetes Center Mergentheim in Bad Mergentheim, Germany. It was published online on May 29, 2025, in Diabetic Medicine . LIMITATIONS: Higher DEPS-10 scores in one fifth of the participants may have been affected by glucagon-like peptide 1 therapy. Additionally, the relatively low positive predictive value of the DEPS-10 could have been attributed to its broader scope in detecting various disordered eating behaviours beyond binge eating disorder. DISCLOSURES: This study was funded by a grant from the German Center for Diabetes Research. The authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. References Credit Lead image: Anastasiia Torianyk/Dreamstime Medscape News UK © 2025 WebMD, LLC Cite this: Novel Survey Effectively Screens Binge Eating in Diabetes - Medscape - June 05, 2025.
Perth Now
2 days ago
- Health
- Perth Now
Why Roger Cook is throwing support behind diabetes research
Premier Roger Cook and senior minister Paul Papalia rallied with families affected by type 1 diabetes on the steps of Parliament House last Thursday morning. Both Mr Cook and Mr Papalia have children who live with the condition, which affects more than 135,000 people nationwide. Type 1 diabetes prevents the body from producing insulin, which is needed to remove glucose from the bloodstream. If left untreated it can be fatal and cause long-term health complications such as kidney, heart, nerve and eye damage, and gum and tooth disease. Your local paper, whenever you want it. It is estimated that about 25,000 Australians are in the early stages of T1 diabetes but are yet to be diagnosed. The gathering at Parliament House was part of a broader awareness campaign led by advocacy group Breakthrough T1D ahead of its Blue Tie Gala this month, which hopes to raise more than $1 million for vital research. Both Mr Cook and Mr Papalia are scheduled to attend the gala. 'Type 1 diabetes doesn't discriminate — it touches families in every corner of our community,' Mr Cook said. 'Today, we stand not only as leaders but as parents united in the mission to raise awareness, drive research and ultimately find a cure.' Mr Papalia said the event would help fund 'life-changing' breakthroughs in T1D research. 'Living with type 1 diabetes is a relentless challenge, but it's one made easier through community, advocacy and support,' he said. 'Events like the Blue Tie Gala are critical in shining a light on the realities of T1D and helping fund the breakthroughs that can change lives.' Mt Lawley entrepreneur Ljupco Taneski, who donates 50 per cent of his company's profits to Breakthrough T1D, was also at Parliament House with his family and daughter Caterina, who lives with the condition. Caterina Taneska (9) with her father Ljupco Taneski. Riley Churchman Credit: Riley Churchman / The West Australian Breakthrough T1D CEO Sydney Yovic said the event, along with the support from the Government and 'generous donors', was incredibly important in the drive towards a cure for T1D. 'The families meeting Premier Cook and Minister Papalia know all too well the burden of living with T1D, and how important it is that we achieve our goal of creating a world without the condition,' she said. The Blue Tie Gala will be held at the Perth Convention and Exhibition centre on June 7. Tickets are available at
Business Recorder
30-05-2025
- Health
- Business Recorder
Free insulin to 250 children: Getz Pharma, NGO sign MoU
ISLAMABAD: In a bid to provide free insulin to children and young people with Type-1-Diabetes (T1D) Getz Pharma and a local non-profit organization (NGO) namely, Meethi Zindagi have signed a memorandum of understanding (MoU) to provide free insulin to 250 children across the country for the rest of their lives. The MoU signing ceremony held here on Thursday, attended by senior officials from both organisations, children with T1D, and their parents. The event featured engaging activities such as face painting and storytelling, where children bravely shared their journeys of living with diabetes. Getz Pharma is Pakistan's largest local pharmaceutical firm and the only company producing insulin locally. The MoU outlines that Getz Pharma will supply insulin on a quarterly basis, based on dose requirements provided by Meethi Zindagi. The non-profit will manage the identification of beneficiaries, ensure safe storage and distribution of the insulin, and provide quarterly reports on usage and outcomes. The participants were informed that during past 20 years over 18,000 children and young people have died due to complications of Type 1 Diabetes largely from lack of access to insulin. 'There are around 26,000 children and young people living with Type 1 Diabetes in Pakistan, but only about 8,000 receive free insulin,' said Dr Sana Ajmal, founder and executive director of Meethi Zindagi. 'With Getz Pharma's support, we are expanding our reach to 1,550 children—across more than 130 cities from Tharparkar to Dera Bugti—by including 250 more in our program,' she added. Dr Sana, herself a T1D patient, launched Meethi Zindagi in 2017 to help families like hers who struggled to afford insulin. Besides free insulin, the non-profit also provides peer support, medical consultations, and psychological help. 'Insulin is a right, not a privilege,' she emphasised. 'It should be available at the doorstep of every child who needs it.' Dr Wajiha Javed, associate director Public Health at Getz Pharma, said the partnership reflects the company's belief in both quality medicines and sustainable health advocacy. 'It is unacceptable that 18,000 children have died simply because they couldn't access insulin,' she said. 'Our commitment goes beyond supply we will also help create peer support networks, launch awareness campaigns for early diagnosis, and support nutritional programmes.' Highlighting Getz Pharma's unique position as the only local manufacturer of insulin in Pakistan, Dr Wajiha assured that the company would not let geographical barriers hinder its mission. 'This collaboration is a first step. We want to ensure that no child is denied a future simply because they can't afford a vial of insulin.' She maintained that during insulin shortages and crises, Getz Pharma ensured an uninterrupted supply by producing insulin locally and delivering it even to remote areas such as Parachinar. It supported thousands of patients and extended critical assistance to institutions like the Children's Hospital and the National Institute of Child Health when others stepped back. In addition to providing insulin, Getz Pharma is driving a broader, patient-focused effort to transform diabetes care in Pakistan. The company actively invests in research, runs public awareness campaigns, conducts community screenings, and supports early diagnosis initiatives. 'With a separate field force deployed nationwide to educate patients, caregivers, and healthcare providers, we ensure better disease management. This holistic approach reflects Getz Pharma's long-term commitment to addressing the root challenges of diabetes care, far beyond the supply of medicine alone', she added. Beyond insulin access, Getz Pharma empowers children with diabetes through education, nutrition support, and school-based programmes, helping them manage their condition and build healthier, informed futures, she added. As the event closed, there was a sense of hope in the air—a hope that with such powerful partnerships, Pakistan can move closer to a future where no child dies from a disease that is entirely manageable with timely access to insulin. Copyright Business Recorder, 2025
Yahoo
29-05-2025
- Business
- Yahoo
TIXiMED Announces Successful Completion of a Phase 1 Study of its Novel Oral Disease-Modifying Type 1 Diabetes Therapy
TIX100 Demonstrates Safety and Tolerability in Human Subjects, Marking a Key Drug Development Milestone Post-Hoc Analysis Reveals Promising First Biological TIX100 Signal in Humans TIXiMED to Advance TIX100 to Multiple Ascending Dose Studies BIRMINGHAM, Ala., May 29, 2025--(BUSINESS WIRE)--TIXiMED, Inc. ( a clinical-stage pharmaceutical company developing a novel disease-modifying oral therapy for type 1 diabetes (T1D), today announced the successful completion of the Phase 1 Single Ascending Dose (SAD) study for TIX100. This first human trial confirmed that TIX100 was safe and well-tolerated across all tested dose levels in healthy subjects. Additionally, post-hoc analysis revealed decreased postprandial blood glucose excursion and improved glucose homeostasis after a standardized liquid meal in the two highest dose cohorts, providing the first evidence of a biological TIX100 effect in humans. "We are thrilled with the successful completion of the Phase 1 SAD study, which demonstrated the safety and tolerability of TIX100 in humans," said Dr. Anath Shalev, Founder and Chief Scientific Officer at TIXiMED. "We are also excited that, despite the small sample size and healthy study population, a promising metabolic TIX100 signal became evident at the human dose predicted in preclinical models," Dr. Shalev added. "These findings also suggest that stronger effects might be observed in people with diabetes and bring TIXiMED closer to delivering a novel oral therapy that addresses the underlying causes of T1D, offering hope for improved outcomes for patients across all stages of the disease." This double-blind, randomized, placebo-controlled Phase 1 SAD study evaluated the safety, tolerability, and pharmacokinetics of TIX100 at escalating doses in 28 healthy adults. Clinical and laboratory results demonstrated no drug-related adverse events, no ECG changes and no hypoglycemia with TIX100 exhibiting a favorable safety profile and predictable pharmacokinetics, supporting progression to the next phase of clinical development. TIX100 is an oral drug that targets thioredoxin-interacting protein (TXNIP), a detrimental protein that is elevated in people with diabetes and leads to beta cell death and pancreatic islet dysfunction. TXNIP inhibition has been demonstrated in mouse models and in humans with T1D to protect the body's own insulin-producing beta cells while promoting overall islet cell health. TIX100 has also been shown to reduce unnecessary glucose production from the liver. TIX100 is a potent and specific TXNIP inhibitor designed to target these underlying disease mechanisms and has been shown to be highly efficacious in preventing and reversing diabetes in pre-clinical studies. Building on these results, TIXiMED is now preparing to initiate a Phase 1 Multiple Ascending Dose (MAD) study to further assess longer-term TIX100 safety, tolerability, and pharmacokinetics over multiple doses in healthy subjects. "Clinical advancement of innovative therapies addressing the fundamental biological causes of T1D is exciting, and supporting these efforts is critical to preventing and delaying T1D disease progression," says Dr. Ben Williams, Program Officer at The Leona M. and Harry B. Helmsley Charitable Trust. "The unique target product profile and mechanism of TIX100 positions it as a promising candidate to transform T1D management," said Steve Daly, CEO of TIXiMED. "We are inspired by these results and excited to advance to the MAD study, continuing our mission to address the unmet needs of people living with T1D." About TIXiMED TIXiMED is a pharmaceutical company dedicated to developing and commercializing a first-of-its kind oral therapy for type 1 diabetes based on inhibition of the protein TXNIP. TIXiMED is the exclusive license holder for the patent surrounding TIX100, a novel, small molecule TXNIP inhibitor, and its derivatives, which has been shown to protect against models of type 1 and type 2 diabetes as well as metabolic dysfunction–associated steatotic liver disease. Visit for more information. The Helmsley Charitable Trust made a Program Related Investment in the form of a loan to support this project. View source version on Contacts Emma BoldenEmail: Emma@ Phone: +1.949.939.8771Website: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
29-05-2025
- Health
- Business Wire
TIXiMED Announces Successful Completion of a Phase 1 Study of its Novel Oral Disease-Modifying Type 1 Diabetes Therapy
BIRMINGHAM, Ala.--(BUSINESS WIRE)-- TIXiMED, Inc. ( a clinical-stage pharmaceutical company developing a novel disease-modifying oral therapy for type 1 diabetes (T1D), today announced the successful completion of the Phase 1 Single Ascending Dose (SAD) study for TIX100. This first human trial confirmed that TIX100 was safe and well-tolerated across all tested dose levels in healthy subjects. Additionally, post-hoc analysis revealed decreased postprandial blood glucose excursion and improved glucose homeostasis after a standardized liquid meal in the two highest dose cohorts, providing the first evidence of a biological TIX100 effect in humans. Building on these results, TIXiMED is now preparing to initiate a Phase 1 Multiple Ascending Dose study to further assess longer-term TIX100 safety, tolerability, and pharmacokinetics over multiple doses in healthy subjects. Share 'We are thrilled with the successful completion of the Phase 1 SAD study, which demonstrated the safety and tolerability of TIX100 in humans,' said Dr. Anath Shalev, Founder and Chief Scientific Officer at TIXiMED. 'We are also excited that, despite the small sample size and healthy study population, a promising metabolic TIX100 signal became evident at the human dose predicted in preclinical models,' Dr. Shalev added. 'These findings also suggest that stronger effects might be observed in people with diabetes and bring TIXiMED closer to delivering a novel oral therapy that addresses the underlying causes of T1D, offering hope for improved outcomes for patients across all stages of the disease.' This double-blind, randomized, placebo-controlled Phase 1 SAD study evaluated the safety, tolerability, and pharmacokinetics of TIX100 at escalating doses in 28 healthy adults. Clinical and laboratory results demonstrated no drug-related adverse events, no ECG changes and no hypoglycemia with TIX100 exhibiting a favorable safety profile and predictable pharmacokinetics, supporting progression to the next phase of clinical development. TIX100 is an oral drug that targets thioredoxin-interacting protein (TXNIP), a detrimental protein that is elevated in people with diabetes and leads to beta cell death and pancreatic islet dysfunction. TXNIP inhibition has been demonstrated in mouse models and in humans with T1D to protect the body's own insulin-producing beta cells while promoting overall islet cell health. TIX100 has also been shown to reduce unnecessary glucose production from the liver. TIX100 is a potent and specific TXNIP inhibitor designed to target these underlying disease mechanisms and has been shown to be highly efficacious in preventing and reversing diabetes in pre-clinical studies. Building on these results, TIXiMED is now preparing to initiate a Phase 1 Multiple Ascending Dose (MAD) study to further assess longer-term TIX100 safety, tolerability, and pharmacokinetics over multiple doses in healthy subjects. 'Clinical advancement of innovative therapies addressing the fundamental biological causes of T1D is exciting, and supporting these efforts is critical to preventing and delaying T1D disease progression,' says Dr. Ben Williams, Program Officer at The Leona M. and Harry B. Helmsley Charitable Trust. 'The unique target product profile and mechanism of TIX100 positions it as a promising candidate to transform T1D management,' said Steve Daly, CEO of TIXiMED. 'We are inspired by these results and excited to advance to the MAD study, continuing our mission to address the unmet needs of people living with T1D.' About TIXiMED TIXiMED is a pharmaceutical company dedicated to developing and commercializing a first-of-its kind oral therapy for type 1 diabetes based on inhibition of the protein TXNIP. TIXiMED is the exclusive license holder for the patent surrounding TIX100, a novel, small molecule TXNIP inhibitor, and its derivatives, which has been shown to protect against models of type 1 and type 2 diabetes as well as metabolic dysfunction–associated steatotic liver disease. Visit for more information. The Helmsley Charitable Trust made a Program Related Investment in the form of a loan to support this project.
